ecancermedicalscience · 2017 · 32 citations · 27 references
MedicineImmunologyOncologyCancer ImmunologyChemotherapyTumor MicroenvironmentBreast Cancer OncologyBreast Surgical OncologyImmuno-oncology BiomarkersLocally Advanced Breast CancerMalignant NeoplasmsTumor-infiltrating LymphocytesBreast Cancer ChemotherapyBreast Cancer HistopathologyBreast Cancer PrognosisBreast Cancer Tumor MicroenvironmentDisease-free Survival AssessmentPrognostic PredictionPrognostic VariablesTriple-negative Breast Cancer Therapy
INTRODUCTION: In locally and locally advanced triple-negative breast cancer (TNBC), neoadjuvant chemotherapy (NAC) only induces a pCR in 30-35% of patients. Clinical and pathological factors are not enough to distinguish the patients who have no chance of a pCR or not. The tumour microenvironment is critical for cancer and tumour-infiltrating lymphocytes (TIL). Moreover, the NAC scenario is the perfect setting to study possible changes in TIL levels. MATERIAL AND METHODS: Using our prospective maintained breast cancer (BC) database, we identified 164 TNBC patients treated with NAC between 1998 and 2015 with enough samples of diagnostic biopsy and after surgery. Evaluation of TILs before and after NAC followed a standardised methodology for visual assessment on haematoxylin-eosin sections and the amounts of TILs were quantitated in deciles. We categorised lymphocyte-predominant breast cancer cutoff according to a receiver operating characteristic (ROC) analysis. We categorised LPBC as involving > 40% lymphocytic infiltration tumour stroma. The primary end point was predictive value of TILs to NAC, and the secondary end point was disease-free survival (DFS). DFS was analysed using the Kaplan-Meier method and the groups were compared with a long-rank test. Univariate and multivariate Cox models were used to generate hazard ratios for determining associations between variables such as TIL after NAC and DFS. RESULTS: = 0.01. Univariate and multivariate analysis confirmed TIL to be an independent prognostic marker of DFS. CONCLUSIONS: Tumour-infiltrating lymphocytes could be routinely used in locally advanced TNBC treated with anthracycline and taxane, such as biomarker, to be enabled the identification of different two subgroups: LPBC patients have a very high response to NAC pCR 88%, meanwhile non-LPBC patients only achieve 9%. Moreover, non-LPBC patients have a worse prognosis than LPBC patients. This data verified the predictive and prognostic value of TIL.
27
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney, Sachet A. Shukla, Catherine J. Wu et al. · Cell · 2015 · 4.1K citations · Full text
Medicine, Immunology, Oncology +17
Alan S. Coates, Eric P. Winer, Aron Goldhirsch et al. · Annals of Oncology · 2015 · 1.8K citations · Full text
Sherene Loi, Nicolas Sirtaine, Fanny Piette et al. · Journal of Clinical Oncology · 2013 · 1.6K citations
Medicine, Immunology, Oncology +17